Vijayam Bio Cytes (Tamil Nadu) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 30-07-2024
- Paid Up Capital ₹ 0.20 M
as on 30-07-2024
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 12.00 Cr
as on 30-07-2024
- Revenue -30.80%
(FY 2023)
- Profit 24.15%
(FY 2023)
- Ebitda 18.18%
(FY 2023)
- Net Worth -17.89%
(FY 2023)
- Total Assets -24.52%
(FY 2023)
About Vijayam Bio Cytes (Tamil Nadu)
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹12.00 Cr.
Kailasam Nagarajan and Padmini Nagarajan serve as directors at the Company.
- CIN/LLPIN
U24200TN2016PTC110875
- Company No.
110875
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jun 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Vijayam Bio Cytes (Tamil Nadu)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kailasam Nagarajan  | Director | 13-Jun-2016 | Current |
| Padmini Nagarajan | Director | 13-Jun-2016 | Current |
Financial Performance of Vijayam Bio Cytes (Tamil Nadu).
Vijayam Bio Cytes (Tamil Nadu) Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 30.8% decrease. The company also saw a substantial improvement in profitability, with a 24.15% increase in profit. The company's net worth observed a substantial decline by a decrease of 17.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vijayam Bio Cytes (Tamil Nadu)?
In 2023, Vijayam Bio Cytes (Tamil Nadu) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vijayam Bio Cytes Private LimitedActive 21 years 2 monthsKailasam Nagarajan and Padmini Nagarajan are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 16 Nov 2021 | ₹12.00 Cr | Open |
How Many Employees Work at Vijayam Bio Cytes (Tamil Nadu)?
Unlock and access historical data on people associated with Vijayam Bio Cytes (Tamil Nadu), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vijayam Bio Cytes (Tamil Nadu), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vijayam Bio Cytes (Tamil Nadu)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
